City Drugs Profile
Key Indicators
- Authorised Capital ₹ 8.00 M
- Paid Up Capital ₹ 7.55 M
- Company Age 32 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.18 Cr
- Revenue Growth -1.31%
- Profit Growth 6.49%
- Ebitda 4.50%
- Net Worth 4.63%
- Total Assets -2.74%
About City Drugs
City Drugs Private Limited (CDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 06 August 1992 and has a history of 32 years and five months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.00 M and a paid-up capital of Rs 7.55 M.
The company currently has active open charges totaling ₹4.18 Cr.
Praveen Narang and Prabhat Narang serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74899DL1992PTC049869
-
Company No.
049869
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Aug 1992
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at City Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prabhat Narang
|
Director | 06-Aug-1992 | Current |
|
Praveen Narang
|
Director | 01-Apr-1997 | Current |
Financial Performance of City Drugs.
City Drugs Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.31% decrease. The company also saw a slight improvement in profitability, with a 6.49% increase in profit. The company's net worth moved up by a moderate rise of 4.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of City Drugs?
In 2023, City Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Prabco Surgimed Private LimitedPraveen Narang and Prabhat Narang are mutual person
Charges (Loans)
₹41.75 M
₹0
Charges Breakdown by Lending Institutions
- Others : 4.18 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Aug 2019 | Others | ₹0.85 M | Open |
| 14 Dec 1999 | Others | ₹4.09 Cr | Open |
How Many Employees Work at City Drugs?
Unlock and access historical data on people associated with City Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of City Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped City Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
